▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3876 by analyst upside · 2026-09-27
MRK
Merck & Co., Inc.
Healthcare · Market Cap $367B · P/E 119.0x
ANALYST PRICE TARGET
+3.3%
implied upside to consensus target
Current Price $148.78
Consensus Target $153.65
Bull Target $186.0
Bear Target $105.0
Analysts Covering 26
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
14
Hold
7
Sell
0
52-Week Low $78.03
52-Week High $156.92
YTD Return +42.6%
FUNDAMENTALS
Market Cap $367B
P/E Ratio (TTM) 119.0x
Forward P/E 15.6x
EPS (TTM) $1.25
PEG Ratio 2.72
Dividend Yield 2.29%
Revenue (TTM) $66.6B
Profit Margin 4.8%
52-WEEK RANGE
52-Week Low $78.03
52-Week High $156.92
Current Price $148.78
Bear Target $105.0
Bull Target $186.0
● Now $148.78 ● Target $153.65
TRADING DATA
Avg Volume 10.0M
YTD Return +42.6%
Analyst Count 26
Consensus Buy
Upside to Target +3.3%
Last Updated 2026-09-27

ANALYST SUMMARY

Merck & Co., Inc. (MRK) is currently trading at $148.78 with a Wall Street consensus price target of $153.65, implying potential upside of 3.3% over the next 12 months. 26 analysts currently cover MRK, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $186.0, while the most cautious has a target of $105.0.

MRK operates in the Healthcare sector with a market capitalisation of $367B. The stock is up 42.6% year-to-date and is currently trading near the upper end of its 52-week range of $78.03 – $156.92.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MRK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HSBC - Reiterated
Buy → Buy 2026-09-10 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-09-09 29% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-09-08 62% win rate (8 calls)
Wells Fargo - Reiterated
Overweight → Overweight 2026-09-04 Building track record
Wolfe Research - Reiterated
Outperform → Outperform 2026-08-25 Building track record
Argus Research - Reiterated
Buy → Buy 2026-08-25 Building track record
Goldman Sachs - Reiterated
Buy → Buy 2026-08-21 Building track record
BMO Capital - Reiterated
Outperform → Outperform 2026-08-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
58
out of 100
Coverage depth
25/30
Consensus clarity
19/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →